

MERGENT INDUSTRIAL

NEW LISTING

April 6, 2010

This Supplemental News Reports is published as required, is part of the annual MERGENT INDUSTRIAL and INTERNATIONAL MANUALS and will be included in the bound 2010 April Monthly News Reports and is published on our Website.

DIAMYD MEDICAL AB

Company Website: www.diamyd.com

History: Founded in Sweden in 1994. Incorporated in Sweden on Mar. 22, 1996 as Synetics Biotechnology AB. Name changed to Biosyn Holding AB in 1996. Present name adopted on Jan. 13, 1999.

In July 2002, Co. established Diamyd, Inc. in the United States. During 2006, Co. acquired Nurel Therapeutics, Inc. Co. paid by a non-cash issue of 317,173 shares of series B at a subscription price of US\$7.69 per share. The license acquired was valued at US\$2,330,000.

Business: Diamyd Medical is a Swedish public company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. Co. develops therapies from two technological platforms in the areas of diabetes and diabetes-related complications. One of the platforms originates from the GAD65 molecule and is the basis for the DiamydO diabetes vaccine. The second platform, NTDDS (Nerve Targeting Drug Delivery System), uses gene therapy to deliver medication directly to nerve cells. Co. possesses a portfolio of three clinical-stage candidate drugs: DiamydO for type I diabetes (Phase III), DiamydO for LADA (Phase II) and the NTDDS product NP2 for chronic pain (Phase I).

Property: Co. maintains its head office in Stockholm, Sweden. Co. also maintains an office in Pittsburgh, PA.

Subsidiaries

(Wholly owned unless otherwise indicated)

Diamyd Therapeutics AB
Mercofia AB (19%)
Diamyd Diagnostics AB
Diamyd Inc. (United States)

Officers

Elisabeth Lindner, President; Chief Executive Officer
Darren Wolfe, Ph.D., Subsidiary Officer - Chief Executive Officer, Diamyd Inc.
Erika Hillborg, Director - Clinical Development
Peter Zerhouni, Director - Business Development
Natalie Jelveh, Director - Business Control
Anna Styruud, Director - Financial Control

Directors

Anders Essen-Moller, Chairman
Lars Jonsson Sam Lindgren, Ph.D.
Henrik Bonde Maria Teresa Essen-Moller
Goran Pettersson

Auditors: Ohrlings PricewaterhouseCoopers AB

Shareholder Relations: Elisabeth Lindner, Chief Executive Officer Tel: 46 8 661 00 26

Annual Meeting: In December

No. of Stockholders: Feb. 26, 2010, 6,043

No. of Employees: Nov. 30, 2009, 18

Address: Karlavagen 108, Stockholm, SE-115 26, Sweden Tel: 46 8 661 00 26 Fax: 46 8 661 63 68 E-mail: anna.styruud@diamyd.com Web: www.diamyd.com

Consolidated Income Account, years ended August 31 (in thousands of Swedish Kronor):

	2009	2008 (revised)	2007 (revised)
Net sales	1,105	1,092	531
Other oper inc	4,295	1,336	540
Tot oper inc	5,400	2,428	1,071
Raw mater & consumables	17	31	18

External research & devel cost	47,218	41,706	29,049
External patents & licenses exps	3,836	1,342	1,908
Personnel	21,059	17,179	13,554
Other external exps	17,515	8,315	10,941
Depreciation, patents		258	403
Depreciation, equip	128	104	146
Tot oper exps	89,773	68,935	56,019
Oper profit (loss)	(84,373)	(66,507)	(54,948)
Dividends fr other bonds	385	380	350
Interest, bank	1,703	2,228	1,480
Fgn currency fluctuation gain	732	(37)	
Interest, bonds & coml papers			1,094
Fin inc	2,435	2,191	2,574
Int exps	250	9	26
Fgn currency fluctuations cost			(1,421)
Finl exps	250	9	1,447
Tot finl inc & exps	2,570	2,562	1,477
Profit (loss) bef tax	(81,803)	(63,945)	(53,471)
Inc tax	(142)	(22)	266
Net profit (loss) for the yr	(81,945)	(63,967)	(53,205)
Common shares (000): Weigh avg no of shares outstg - basic	22,002	20,418	19,545
Weigh avg no of shares outstg - diluted	22,002	20,418	19,545
Yr end shares	22,365	21,803	19,545
Net earnings (loss) per sh-basic	Sk(3.70)	Sk(3.15)	Sk(2.75)
Net earnings (loss) per sh-diluted	Sk(3.70)	Sk(3.15)	Sk(2.75)
Reclassified to conform with 2009 presentation.			
Adjusted for 100% stock dividend, January 29, 2010			

Consolidated Balance Sheet, as of August 31 (in thousands of Swedish Kronor):

	2009	2008 (revised)
Assets:		
Intang assets	16,627	16,627
Tang assets, gross	996	893
Less: accum deprec - tang assets	631	503
Tang assets	365	390
Finl assets	21,418	21,418
Tot non-curr assets	38,410	38,435
Invent	25	12
Trade receiv	4	123
Other receiv	1,603	750
Ppd tax	822	911
Ppd patent fees	607	458
Ppd ins fees	269	172
Accrued int inc	155	1,259
Other ppd exps	1,987	325
Ppd exps & accrued inc	3,018	2,214

Finl instruments avail-for-sale	7,841	6,402
Liquid assets	37,287	81,890
Tot curr assets	50,600	92,302
Tot assets	89,010	130,737
Liabilities:		
Issued cap	11,183	10,902
Other cap contrib	451,924	424,115
Other res	160	271
Retain earnings (accum losses) incl	(392,550)	(314,512)
Tot shhlders eq	70,717	120,776
Trade pays	11,651	6,101
Other pays	969	839
Accrued vacation pay	279	272
Accrued social security exps	881	308
Accrued expenses, clinical trials	2,524	1,576
Accrued expenses, admin	605	395
Other exps	1,384	470
Ppd inc & accrued exps	5,673	3,021
Tot curr liabil	18,293	9,961
Tot liabil & stkhlders eq	89,010	130,737

Capital Stock: 1. Diamyd Medical AB series A; par Sk1.00

OUTSTANDING—Aug. 31, 2009, 561,671 shs; par Sk1.00

STOCK SPLITS—SEK1.00 par shares split 2-for-1 in 100% stock dividend on Jan. 29, 2010.

OWNERSHIP—As of Aug. 31, 2009, Anders Essen-Moller held 561,671 class A shares representing 100% of Co. s outstanding class A shares outstanding.

VOTING RIGHTS—Entitled to one vote per share.

CONVERTIBLE—Owners of class A shares have right to convert their class A shares into class B shares.

RIGHTS ISSUE—During 1996, Co. conducted a rights offering. In the rights offering, Co. issued to its stockholders nontransferable rights to subscribe for up to 785 and 770,550 additional shares of its series A and series B capital shares, respectively.

During 1997, Co. conducted a rights offering. In the rights offering, Co. issued to its stockholders non-transferable rights to subscribe for up to 150,785 and 1,385,625 additional shares of its series A and series B capital shares, respectively.

During 1999, Co. conducted a rights offering. In the rights offering, Co. issued to its stockholders non-transferable rights to subscribe for up to 75,390 and 692,815 additional shares of its series A and series B capital shares, respectively.

During 2001, Co. conducted a rights offering. In the rights offering, Co. issued to its stockholders non-transferable rights to subscribe for up to 94,240 and 667,974 additional shares of its series A and series B capital shares, respectively.

During 2003, Co. conducted a rights offering. In the rights offering, Co. issued to its stockholders non-transferable rights to subscribe for up to 2,318,189 additional shares of its series B capital shares.

MERGENT MANUALS (ISSN 0895-3252) is published weekly on Tuesday by Mergent 60 Madison Ave., New York, NY 10010. Subscription rate \$647.50 per annum for the News Report portion of the Mergent Manuals service in the United States and Canada (Not to be sold separately from the Manual). Copyright © 2008 by Mergent. All Information contained herein is copyrighted in the name of Mergent and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without prior written consent.

All information contained herein is obtained by MERGENT, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error as well as other factors, however, such information is provided "as is" without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall MERGENT have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if MERGENT is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.

2. Diamyd Medical AB series B; par Sk1.00

OUTSTANDING —Aug. 31, 2009, 10,620,801 shs; par Sk1.00

STOCK SPLITS —SEK1.00 par shares split 2-for-1 in the form of 100% stock dividend on Jan. 29, 2010.

OWNERSHIP —As of Aug. 31, 2009, Bertil Lindkvist held 3,900,303 shares, representing 34.88% of Co. s outstanding class B share capital.

VOTING RIGHTS —Entitled to one tenth of a vote per share.

OPTIONS —Aug. 31, 2009, outstanding, 148,500.

PRIMARY EXCHANGE —Stockholm (STO): DIAM B

SECONDARY EXCHANGES —National Bulletin Board (NBB): DMYDF

PRICE RANGE —(fiscal years, in SEK):

	2009	2008	2007
High	103.50	100.00	172.00
Low	48.50	58.25	60.50

RIGHTS ISSUE —During 1996, Co. conducted a rights offering. In the rights offering, Co. issued to its stock-

holders nontransferable rights to subscribe for up to 785 and 770,550 additional shares of its series A and series B capital shares, respectively.

During 1997, Co. conducted a rights offering. In the rights offering, Co. issued to its stockholders non-transferable rights to subscribe for up to 150,785 and 1,385,625 additional shares of its series A and series B capital shares, respectively.

During 1999, Co. conducted a rights offering. In the rights offering, Co. issued to its stockholders non-transferable rights to subscribe for up to 75,390 and 692,815 additional shares of its series A and series B capital shares, respectively.

During 2001, Co. conducted a rights offering. In the rights offering, Co. issued to its stockholders non-transferable rights to subscribe for up to 94,240 and 667,974 additional shares of its series A and series B capital shares, respectively.

During 2003, Co. conducted a rights offering. In the rights offering, Co. issued to its stockholders non-transferable rights to subscribe for up to 2,318,189

additional shares of its series B capital shares.

3. Diamyd Medical AB American Depositary Receipts; no par.

One American Depositary Receipt equals one Common share.

STOCK SPLITS —No par shares split in the form of a 100% stock dividend on Jan. 29, 2010.

DIVIDENDS —

2009 2.51

DEPOSITARY —Bank of New York Mellon

PRIMARY EXCHANGE —Over-the-Counter (OTC):

DMYDY

PRICE RANGE —

	2009	2008	2007
High	28.25	15.15	22.15
Low	7.00	6.20	8.95